This webinar delves into the dynamic landscape of COAs, examining their historical use and significance, current uses and best practices, and making a case for greater standardization in their implementation.
Watch this webinar exploring real challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases to support clinical development through commercial post-approval.
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to methods for incorporating patient voice in the development of new therapeutics, specifically as part of clinical trials.
As science has enabled care for previously untreatable, ultra-rare conditions, health systems and governments are struggling with ways of financing research and development of these therapies. What are the solutions when the science has progressed, but the economics haven't?
The political issues circling the FDA this year could potentially ripple into biopharma on a scale that’s never been seen before. All eyes are on the FDA’s response to recent court rulings around the abortion pill mifepristone — and the potential effects on other approvals that might be questioned. What does the future look like, exactly? Join Endpoints’ Senior Editor Zachary Brennan in an expert panel to unpack what may come next. We’ll also touch on how the FDA is looking for new ways to spur more rare disease drug development with a fireside chat.
The promise of improving patient care and outcomes through RWD has been understood for some time, but overcoming the fragmentation and inaccessibility of disparate data sources across disease states has proven to be a hard challenge across the industry. We’re not learning fast enough— this is where clinical expert-led AI can help.
By using AI to standardize unprecedented volumes of data, uncover clinical details that have previously been hidden in free text notes, and represent full patient journeys in near real-time, researchers can ask and answer complex questions for targeted populations like never before.
As the volume of the real word evidence data increases, the mechanisms to collect and translate the data into meaningful insights for pharmaceutical organisations becomes increasingly complex. Advances in technologies such as artificial technology have delivered global excitement, but mastering how to leverage AI for meaningful patient outcomes remains uncracked.
Our present healthcare system focuses on treating people when they are ill rather than keeping them healthy. We have been using big data and remote monitoring approaches to monitor people while they are healthy to keep them that way and detect disease at its earliest moment presymptomatically. We use advanced multiomics technologies (genomics, immunomics, transcriptomics, proteomics, metabolomics, microbiomics) as well as wearables and microsampling for actively monitoring health. Following a group of 109 individuals for up to 13 years revealed numerous major health discoveries covering cardiovascular disease, oncology, metabolic health and infectious disease. We have also found that individuals have distinct aging patterns that can be measured in an actionable period of time. Finally, we have used wearable devices for early detection of infectious disease, including COVID-19 as well as microsampling for monitoring and improving lifestyle. We believe that advanced technologies have the potential to transform healthcare and keep people healthy.
Market access is the bridge between clinical and commercial functions, and plays a pivotal role in product launch. Success in market access is defined by the outcome of payer decisions – whether nationally or regionally. While measuring global market access performance has been on the agenda for some time, understanding success is becoming a priority at board and leadership level.
From real-world data to social media, there is more information available to medical affairs teams than ever before. In theory, it should be easier than ever to keep the business aligned with patient and customer needs, yet in practice, the process of insights management is rarely optimized across the organization.
The L7|LIVE SF seminar will explore the ways in which digital technologies, such as unified platforms, are revolutionizing the biotech and life science industries, transforming business models, breaking down data silos, reducing turnaround times, and creating more consistent and reproducible processes. Our panel of experts will share their insights and experiences on these needed cutting-edge technologies and the trends laying the foundation for the future of life sciences.
Health systems are reimagining the hospital of the future. New technologies like real-time asset tracking, artificial intelligence, and applied virtual/augmented reality will be integral to delivering next-generation, interventional care with real-time insights at the point of care. But an infrastructure transformation will be necessary to deliver those capabilities and power innovation roadmaps.
Join Jonathan Edelheit, Chairman and Co-founder of the Corporate Wellness Association as he talks about the Certified Corporate Wellness Specialist and find out if it is the right certification for you. The Certified Corporate Wellness Specialist program is designed to help organizations improve the health and well-being of their employees while also reducing healthcare costs. The program includes 11 modules that cover topics such as leadership, culture, cost savings, mental health, wellness technology, employee well-being, diversity, equity, and inclusion. It also covers the essentials of program design, delivery, and evaluation.
A panel discussion will examine how connected communities using data-driven, virtual and automated technologies are advancing and refining population health strategies. Discover ways health leaders can advance interoperability, intelligent processing and data security so their organizations can respond to consumer demands and take on risk.
Join us as we discuss how the healthcare landscape is changing in technology and clinical trial innovation, including diversity improvement, leveraging real-world evidence, comparative arms, and decentralized clinical trials.
Looking to empower your organizations with high quality patient data? Human abstraction has long been considered the gold standard for extracting high quality information from EHR data. With the rise of NLP, large language models, and machine learning, the question becomes: how should we evaluate these new technologies against the traditional abstraction methods?
The International Agency for Research on Cancer (IARC) published a report called "Global Cancer Observatory" which shows that in 2020, almost 20 million new cancer cases were reported worldwide, leading to almost 10 million deaths. The prevalence of cancer worldwide over a five-year period exceeds 50 million cases. According to the same report, by 2040, the number of new cancer cases per year is expected to reach 30.2 million, representing a 57% increase compared to 2020.
The centerpiece of the Health Affairs Journal Club meeting in May is, “Benchmarking Changes And Selective Participation In The Medicare Shared Savings Program.”
The authors of the study found that since the 2017 introduction of regional spending into the Medicare Shared Savings Program (MSSP) benchmarks, participation incentives were radically altered, favoring the participation of Accountable Care Organizations and practices with lower baseline spending in their region compared to others. These changes suggest additional costs for the program, and the need for reforms.
On May 10, please join author Peter Lyu of RTI International, for a detailed discussion of the paper’s data, methods, and policy conclusions. Health Affairs Senior Editor Laura Tollen will host.
We’ve all seen the studies showing data-driven organizations grow faster, are more profitable, and have a faster time to market. Why does gaining insights from data seem to take so long? In this webinar, we will review practical and successful approaches to executing on a doable data strategy.
In this webinar presented by EXL Health, you’ll hear engaging discussions from industry leaders on how healthcare organizations can harness the power of data to achieve a sustainable business advantage. Centered around the building blocks of data-led value creation, cloud enabled solutions, and enterprise architecture, you’ll discover the steps needed to turn your data into a trusted, strategic asset.
Patients have been very clear: They want care that is convenient and accessible, personalized and streamlined — and often, delivered outside of the hospital. By 2025, expenditures on in-home care services for Medicare fee-for-service and Medicare Advantage beneficiaries could reach $265 billion, creating new challenges and opportunities for the technology that powers the distributed care model.
Siloed systems, data and processes are stalling digital transformation. For healthcare organizations to truly gain a 360-degree view of their patients and providers, critical data currently scattered across various systems needs to be brought together in one place.